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Regarding	 the	 wide	 gene;c	 and	 an;genic	 variability	 of	 Inﬂuenza	
viruses,	 overall	 or	 subtype	 Inﬂuenza	 vaccine	 eﬀec;veness	 (IVE)	
es;mates	 may	 not	 be	 suﬃcient	 to	 assess	 vaccine	 protec;on	 against	
circula;ng	strains.	This	is	par;cularly	important	when	low	IVE	against	a	
speciﬁc	clade	is	suspicious	or	a	new	driSed	virus	is	emerging.		
	
Viral	 gene;c	 characteriza;on	 is	 rou;nely	 performed	 in	 Inﬂuenza	
surveillance	but	viruses	are	selected	according	pa;ent	age,	severity	and	
vaccine	 status.	 For	 instance,	 last	 season	 gene;c	 characterized	 cases	
were	more	vaccinated	than	those	not	selected.	
DESCRIPTION	OF	THE	PROBLEM	
A	protocol	for	virological	data	integra;on	on	IVE	studies	within	I-MOVE	
network		was	performed.	It	intended	to	solve	the	following:	
•  Selec;on	of	the	clade	of	interest	to	provide	IVE;	
•  Determina;on	 of	 the	 number	 of	 cases	 needed	 for	 gene;c	
characteriza;on;	
•  Selec;on	 of	 cases	 for	 gene;c	 characteriza;on	 independently	 of	
pa;ent	features.		
SELECTION	OF	TARGET	INFLUENZA	VIRUS	
Dominant	Inﬂuenza	virus	 	in	circula;on	was	iden;ﬁed	and	the	subtype	
of	 interest	 for	 virus	 characteriza;on	 was	 targeted	 using	 surveillance	
data	(Na;onal	and	European	level).	
PERFORMANCE	OF	GENETIC	CHARACTERIZATION	
Sequencing	 was	 performed	 directly	 from	 the	 clinical	 specimen.	 Only	
when	ampliﬁca;on	cannot	be	obtained	in	the	primary	sample,	sequence	
was	performed	in	isolated	virus	(cell	culture	supernantant).	 
RANDOM	CASE	SELECTION	BY	INFLUENZA	PHASE	
Case	 selec;on	 for	 gene;c	 characteriza;on	 was	 performed	 in	 three	
phases	established	according	to	inﬂuenza	ac;vity	(Figure	1).	
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During	 the	 2015/2016	 season,	 a	 closely	
contact	 between	 epidemiological	 and	
laboratorial	 teams	 allows	 to	 perform	 a	
random	 selec;on	 of	 inﬂuenza	 cases	 for	
gene;c	 characteriza;on	 independently	 of	
cases	features.	
Inﬂuenza	A(H1N1)pdm09	was	the	 	selected	
subtype	 given	 its	 predominance	 and	 the	
emergence	of	new	subclades	 (6B.1	and	6B.
2).	
A	 total	 of	 133	 samples	 were	 gene;c	
characterized	 distributed	 in	 the	 3	 phases.	
(Figure	2).	
Figure	1.	ILI	incidence	rate	and	selec;on	phases	in	the	2015/2016	season	
Figure	2.	Distribu;on	of	gene;c	clades	and	ILI	incidence	rate	per	week	of	symptoms	
onset;	iden;ﬁca;on	of	selec;on	phases	and	respec;ve	characteriza;on	rates	(%).		
		n	(%)	
Ct	value	
<20	 20-29	 30-35	 >35	
A(H1)pdm09	
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Total	selected	
viruses		
(93/116)		
80.2%	
(6/6)		
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74.2%	
(4/6)		
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Table	2.	Inﬂuenza	A(H1)pdm09	viruses	selected	for	gene;c		
															characteriza;on	during	2015/2016	season	
Gene;c	characteriza;on		 p	
							(-)	 (+)	
		Mean	age	(years)	 						49.2	 46.0	 0.382		
		Female	(%)	 							35.0	 56.5	 0.062	
		Inﬂuenza	seasonal			
		vaccine	(%)	 							18.2	 10.1	 0.468	
Table	1.	Characteris;cs	of	2015/2016	EuroEVA	cases	by		gene;c	
																characteriza;on	
No	diﬀerences	 regarding	age,	 sex	and	 inﬂuenza	seasonal	
vaccina;on	 status	 were	 found	 between	 selected	 and	
unselected	cases	for	gene;c	characteriza;on	(Table	1).	
Notes:	p	-	p	value	
The	 success	 of	 the	 gene;c	 characteriza;on	 decreases	 with	
increasing	Ct	value,	ranging	from	100%	of	success	in	samples	
with	Ct	<	20	to	66.7%	in	samples	with	Ct	>35	(Table	2).		
Notes:	Ct	value	-	threshold	cycle	of	Protein	Chain	Reac;on	(PCR)			
The	large	sample	size	needed	to	es;mate	IVE	against	a	speciﬁc	clade	requires	an	important	eﬀort	on	gene;c	characteriza;on	
behind	virological	surveillance.		
However,	random	selec;on	of	cases	for	gene;c	characteriza;on	along	season	seems	to	be	feasible	without	interfering	with	
virological	surveillance	and	allows	to	obtain	a	representa;ve	sample	of	cases	of	the	clade	of	interest.	
•  Virological	data	from	randomly	selected	cases	will	permit	to	es;mate	IVE	against	a	speciﬁc	clade	during	Inﬂuenza	season.	
•  An	extra	eﬀort	on	inﬂuenza	gene;c	characteriza;on	is	necessary	to	achieve	the	needed	sample	size.		
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